Understand the source comparison
Glow Stack 60s Age Specific Protocol: Multi-Pathway Comparison
Thymalin Thymic epithelial stimulation → increased thymulin secretion and naïve T-cell output 10mg subcutaneous weekly or twice weekly CD4+/CD8+ T-cell counts, immunoglobulin levels 8–12 weeks Critical for immune resilience. Addresses the root cause (thymic in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic epithelial stimulation → increased thymulin secretion and naïve T-cell output
- 10mg subcutaneous weekly or twice weekly
- CD4+/CD8+ T-cell counts, immunoglobulin levels
- 8–12 weeks
- Critical for immune resilience. Addresses the root cause (thymic involution) rather than treating symptoms of immunosenescence
- MK-677
- Ghrelin receptor agonist → pulsatile GH release and sustained IGF-1 elevation
- 12.5–25mg oral daily (evening)
- Plasma IGF-1, lean mass, fasting glucose
- 4–6 weeks
- Foundation compound. Without adequate IGF-1 signaling, thymalin and cerebrolysin cannot reach full therapeutic potential
- Cerebrolysin
- Exogenous neurotrophic factors (BDNF, NGF, CNTF) → synaptic remodeling and neuroprotection
- 5–10mL intramuscular 2–3× weekly for 8–12 weeks
- Cognitive testing (MoCA, MMSE), hippocampal volume on MRI
- 10–12 weeks
- Most underutilized compound in Western longevity protocols despite 30+ years of clinical evidence in neurodegeneration trials
- Single-pathway approach (e.g., MK-677 alone)
- GH/IGF-1 axis only
- 25mg oral daily
- Plasma IGF-1
- Shows initial promise but plateaus within 12–16 weeks as thymic and neuroplastic deficits remain unaddressed. Limited sustained benefit